Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin

Clinical Cancer Research

Volumn 16, Issue 20, 2010, Pages 5048-5057

  Hummel, Trent R ^a   Jessen, Walter J ^a   Miller, Shyra J ^a   Kluwe, Lan ^b   Mautner, Victor F ^b   Wallace, Margaret R ^c   Lázaro, Conxi ^d   Page, Grier P ^e   Worley, Paul F ^f   Aronow, Bruce J ^a   Schorry, Elizabeth K ^a   Ratner, Nancy ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF FLORIDA   (United States)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e RTI INTERNATIONAL   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; BIOLOGICAL MARKER; SCATTER FACTOR;

ADOLESCENT; ADULT; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NEUROFIBROMA; NEUROFIBROMATOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SCHWANN CELL; UMBILICAL VEIN; WESTERN BLOTTING;

ADOLESCENT; ADRENOMEDULLIN; ADULT; CELL MOVEMENT; CHILD; CHILD, PRESCHOOL; CULTURE MEDIA; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 1; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SCHWANN CELLS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77958052974     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0613     Document Type: Article

References (52)

1. Rasmussen SA, Friedman JM. NF1 gene and neurofibromatosis 1. Am J Epidemiol 2000;151:33-40.
2. Legius E, Marchuk DA, Collins FS, Glover TW. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 1993;3:122-6. (Pubitemid 23079793)
3. Listernick R, Louis DN, Packer RJ, Gutmann DH. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997;41:143-9. (Pubitemid 27082094)
4. Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer 1994;70:969-72. (Pubitemid 24331097)
5. Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet 1995;11:90-2.
6. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002;39:311-4. (Pubitemid 34526349)
7. Zoller ME, Rembeck B, Oden A, Samuelsson M, Angervall L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997;79:2125-31. (Pubitemid 27227376)
8. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003;3:685-94.
9. McCaughan JA, Holloway SM, Davidson R, et al. Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1. J Med Genet 2007;44:463-6. (Pubitemid 47056874)
10. Miser JS, Triche TJ, Kinsella TJ, Pritchard DJ. Other soft tissue sarcomas of childhood. 4th ed. Philadelphia (PA): Lippincott Williams &Wilkins; 2002.
11. 18F]2-fluoro-2-deoxy- D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 2008;19:390-4.
12. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
13. Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer. Lancet 2003;361:1122-8.
14. Ishikawa O, Ishikawa H. Neurofibroma-derived fibroblast-stimulating factor in the serum of patients with neurofibromatosis (von Recklinghausen's disease). Arch Dermatol Res 1985;277:433-8.
15. Riccardi VM. Growth-promoting factors in neurofibroma crude extracts. Ann N Y Acad Sci 1986;486:206-26.
16. Riopelle RJ, Riccardi VM, Faulkner S, Martin MC. Serum neuronal growth factor levels in von Recklinghausen's neurofibromatosis. Ann Neurol 1984;16:54-9.
17. Mashour GA, Ratner N, Khan GA, Wang HL, Martuza RL, Kurtz A. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 2001;20:97-105.
18. Jensen CH, Schroder HD, Teisner B, Laursen I, Brandrup F, Rasmussen HB. Fetal antigen 1, a member of the epidermal growth factor superfamily, in neurofibromas and serum from patients with neurofibromatosis type 1. Br J Dermatol 1999;140:1054-9.
19. Miller SJ, Rangwala F, Williams J, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 2006;66:2584-91.
20. Moriyama T, Kataoka H, Kawano H, et al. Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas and schwannomas in humans. Cancer Lett 1998;124:149-55.
21. Grant DS, Kleinman HK, Goldberg ID, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A 1993;90:1937-41.
22. Su W, Gutmann DH, Perry A, Abounader R, Laterra J, Sherman LS. CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro. Glia 2004;45:297-306. (Pubitemid 38222258)
23. Rao UN, Sonmez-Alpan E, Michalopoulos GK. Hepatocyte growth factor and c-MET in benign and malignant peripheral nerve sheath tumors. Hum Pathol 1997;28:1066-70. (Pubitemid 27388108)
24. Fukuda T, Ichimura E, Shinozaki T, et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int 1998;48:757-62.
25. Krasnoselsky A, Massay MJ, DeFrances MC, Michalopoulos G, Zarnegar R, Ratner N. Hepatocyte growth factor is a mitogen for Schwann cells and is present in neurofibromas. J Neurosci 1994;14:7284-90.
26. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192:553-60.
27. Zudaire E, Martinez A, Cuttitta F. Adrenomedullin and cancer. Regul Pept 2003;112:175-83.
28. Hague S, Zhang L, Oehler MK, et al. Expression of the hypoxically regulated angiogenic factor adrenomedullin correlates with uterine leiomyoma vascular density. Clin Cancer Res 2000;6:2808-14.
29. Iimuro S, Shindo T, Moriyama N, et al. Angiogenic effects of adrenomedullin in ischemia and tumor growth. Circ Res 2004;95:415-23.
30. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-oncol 2005;7:134-53.
31. Ouafik L, Sauze S, Boudouresque F, et al. Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. Am J Pathol 2002;160:1279-92.
32. Chen Y, Zhang Y, Yin Y, et al. SPD - a web-based secreted protein database. Nucleic Acids Res 2005;33:D169-73.
33. Miller SJ, Jessen WJ, Mehta T, et al. Integrative genomic analyses of neurofibromatosis tumors identify SOX9 as biomarker and survival gene. EMBO Mol Med 2009;1:236-48.
34. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
35. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001;125:279-84. (Pubitemid 33000466)
36. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 2005;53:35-69. (Pubitemid 39656109)
37. Zimmermann U, Fischer JA, Frei K, Fischer AH, Reinscheid RK, Muff R. Identification of adrenomedullin receptors in cultured rat astrocytes and in neuroblastoma x glioma hybrid cells (NG108-15). Brain Res 1996;724:238-45. (Pubitemid 26244538)
38. Martinez A, Vos M, Guedez L, et al. The effects of adrenomedullin over-expression in breast tumor cells. J Natl Cancer Inst 2002;94:1226-37.
39. Oehler MK, Norbury C, Hague S, Rees MC, Bicknell R. Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth. Oncogene 2001;20:2937-45.
40. Ishikawa T, Chen J, Wang J, et al. Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis. Oncogene 2003;22:1238-42.
41. Hay DL, Howitt SG, Conner AC, Schindler M, Smith DM, Poyner DR. CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS. Br J Pharmacol 2003;140:477-86.
42. Kim W, Moon SO, Sung MJ, et al. Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells. FASEB J 2003;17:1937-9.
43. Morimoto A, Okamura K, Hamanaka R, et al. Hepatocyte growth factor modulates migration and proliferation of human microvascular endothelial cells in culture. Biochem Biophys Res Commun 1991;179:1042-9.
44. Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T, Papadakis N, Varakis I. Microvessel density in brain tumors. Anticancer Res 1997;17:4747-53.
45. Simpson A, Grimer R, Mangham C, Cullinane C, Lewis I, Burchill SA. MVD predicts disease-free and overall survival in tumours of the Ewing's sarcoma family (ESFT). Br J Cancer 2002;86:P202.
46. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
47. Mok SC, Chao J, Skates S, et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001;93:1458-64.
48. Huddleston HG, Wong KK, Welch WR, Berkowitz RS, Mok SC. Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol 2005;96:77-83.
49. Pavel ME, Hoppe S, Papadopoulos T, et al. Adrenomedullin is a novel marker of tumor progression in neuroendocrine carcinomas. Horm Metab Res 2006;38:112-8.
50. Dotsch J, Hanze J, Knufer V, et al. Increased urinary adrenomedullin excretion in children with urinary tract infection. Nephrol Dial Transpl 1998;13:1686-9.
51. Hsieh CS, Huang LT, Lee SY, et al. Evaluation of hepatocyte growth factor in patients with biliary atresia. J Pediatr Surg 2008;43:1333-7.
52. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006;66:1721-9.